Drug developer GSK is vacating its 635,000-square-foot life sciences lab in Rockville, Maryland, where it was the sole tenant ...

Starting from September 2025, eligible Singaporeans and permanent residents will be able to receive means-tested subsidies of up to 75 percent for Shingrix, the only vaccine currently approved by the ...

With an estimated 2.1 million children in Nigeria and almost one million in Ethiopia1 classed as 'zero dose', having never ...

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

The acquisition will enable it to expand its offerings by introducing tailored, high-value logistics solutions across a wide range of sectors, Shadowfax said in a statement on Monday. “We are excited ...

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I’ve investigated whether this is the case. When investing, your capital is ...

Both assets are poised to enter registrational studies under accelerated approval pathways, according to Jefferies. GSK to Stay Out of Obesity—but not GLP-1s At JPM25 on Monday, GSK Chief Scientific ...

Brand New Membership Level: Benzinga Trade Alerts GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from existing assets. At the JPMorgan Healthcare ...

Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can expand knowledge ...

Eli Lilly made a $2.5 billion deal for a breast cancer drug; GSK reached a $1 billion-plus deal for IDRx. The announcements suggest a potential rebound in M&A deals in the healthcare sector for 2025.